Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease

• Prif Awduron: Niurys de Castro-Suárez (Awdur), Mirjam N. Trame (Awdur), Mayra Ramos-Suzarte (Awdur), José M. Dávalos (Awdur), Raymed A. Bacallao-Mendez (Awdur), Anaelys R. Maceo-Sinabele (Awdur), Víctor Mangas-Sanjuán (Awdur), Gledys Reynaldo-Fernández (Awdur), Leyanis Rodríguez-Vera (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: MDPI AG, 2020-11-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease characterized by an overexpression of epidermal growth factor receptor (EGFR). Nimotuzumab is a recombinant humanized monoclonal antibody against human EGFR. The aim of this study was to develop a population pharmacokinetic mo...